Soleno

Soleno Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on Prader-Willi syndrome (PWS). In March 2025, the company achieved a landmark milestone by securing FDA approval for the first and only therapy that targets hyperphagia in PWS patients, positioning Soleno as a pioneer in this niche therapeutic area. Leveraging a science-driven approach combined with strong advocacy and community engagement, Soleno delivers patient-centric solutions that address unmet medical needs. The company’s culture emphasizes collaboration, scientific rigor, and a commitment to improving quality of life for individuals affected by rare disorders.